TXA Central
TXA Central is a resource for health professionals caring for patients with acute severe bleeding
Year: 2020
World Health Organization reacts to the WOMAN Trial results
In response to the release of the WOMAN trial results, the World Health Organisation (WHO) department of reproductive health and research is working with the Cochrane Pregnancy and Childbirth group to fast-track the update of the existing Cochrane systematic review on the treatment of primary postpartum hemorrhage (PPH) with priority given to the use of
Details
Trauma-INTACT Results
The Trauma Intact trial: a clinical trial investigating pharmacokinetics of intramuscular tranexamic acid (TXA) in bleeding trauma patients TXA a drug that prevents severe bleeding after injury by inhibiting blood clot breakdown, is most effective when given soon after injury. Every 15 minutes treatment delay reduces its lifesaving potential by 10%. However, currently only 3%
Details
Nigerian Health Minister To Support the WOMAN-trial
Nigeria’s health minister, Professor Isaac Adewale has said that deaths of women due to postpartum haemorrhage (PPH), a severe form of bleeding after childbirth, was a huge problem in Nigeria and that he will promote the use of tranexamic acid to reduce these deaths. “This drug is not new in Nigeria, but now we want
Details